Form 4

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Aklog Lishan	2. Issuer Name and Ticker or Trading Symbol PAVmed Inc. [ PAVM ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __ X __ Director __ X __ 10% Owner __ X __ Officer (give title below) _____ Other (specify below) Chairman and CEO
(Last) (First) (Middle) ONE GRAND CENTRAL PLACE, SUITE 4600	3. Date of Earliest Transaction (MM/DD/YYYY) 9/7/2017
(Street) NEW YORK, NY 10165 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person _ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	9/7/2017		P		850	A	⁽¹⁾	65038	D
Common Stock	9/8/2017		P		400	A	⁽²⁾	65438	D
Common Stock								285	I	By daughter
Common Stock								300	I	By son
Common Stock								5713879	I	By HCFP/Capital Partners III LLC ⁽⁴⁾
Common Stock								2520532	I	By Pavilion Venture Partners LLC ⁽⁵⁾
Common Stock								87020	I	By HCFP Inc. ⁽⁶⁾
Common Stock								125000	I	By HCFP/Capital Partners IIIB LLC ⁽⁷⁾
Common Stock								20000	I	By HCFP/AG LLC ⁽⁸⁾

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Warrants	$5.00	9/7/2017		P		200		10/28/2016	1/29/2022	Common Stock	200	$1.20	49800	D
Warrants	$5.00	9/8/2017		P		300		10/28/2016	1/29/2022	Common Stock	300	⁽³⁾	50100	D
Warrants	$5.00							10/28/2016	1/29/2022	Common Stock	5713879		5713879	I	By HCFP/Capital Partners III LLC ⁽⁴⁾
Warrants	$5.00							10/28/2016	1/29/2022	Common Stock	2220532		2220532	I	By Pavilion Venture Partners LLC ⁽⁵⁾
Warrants	$5.00							10/28/2016	1/29/2022	Common Stock	387020		387020	I	By HCFP Inc. ⁽⁶⁾
Warrants	$5.00							10/28/2016	1/29/2022	Common Stock	125000		125000	I	By HCFP/Capital Partners IIIB LLC ⁽⁷⁾
Warrants	$5.00							10/28/2016	1/29/2022	Common Stock	20000		2000	I	By HCFP/AG LLC ⁽⁸⁾

Explanation of Responses:
(1)	The shares were purchased at a weighted average price of approximately $5.11297047 per share. These shares were purchased in multiple transactions at prices ranging from $4.74 to $5.95, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote to this Form 4.
(2)	The shares were purchased at a weighted average price of approximately $5.98 per share. These shares were purchased in multiple transactions at prices ranging from $5.73 to $6.25, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote to this Form 4.
(3)	The warrants were purchased at a weighted average price of approximately $1.3167per warrant. These warrants were purchased in multiple transactions at prices ranging from $1.15 to $1.45, inclusive. The reporting person undertakes to provide PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants purchased at each separate price within the ranges set forth this footnote to this Form 4.
(4)	Dr. Aklog is a member and a co-manager of HCFP/Capital Partners III LLC, and shares joint voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his proportionate pecuniary interest therein.
(5)	Dr. Aklog is a member and sole manager of Pavilion Venture Partners LLC, and has sole voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his proportionate pecuniary interest therein.
(6)	Dr. Aklog is a controlling shareholder of HCFP Inc., and shares joint voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his proportionate pecuniary interest therein.
(7)	Dr. Aklog is a member and a co-manager of the entity that acts as sole manager of HCFP/Capital Partners IIIB LLC, and shares joint voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his pecuniary interest therein.
(8)	Dr. Aklog is a co-manager of HCFP/AG LLC, and shares joint voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his pecuniary interest therein.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Aklog Lishan ONE GRAND CENTRAL PLACE SUITE 4600 NEW YORK, NY 10165	X	X	Chairman and CEO
HCFP/Capital Partners III LLC ONE GRAND CENTRAL PLACE SUITE 4600 NEW YORK, NY 10165		X
Pavilion Venture Partners LLC ONE GRAND CENTRAL PLACE SUITE 4600 NEW YORK, NY 10165		X

Signatures
/s/ Dr. Lishan Aklog		9/11/2017
^** Signature of Reporting Person		Date
/s/ Dr. Lishan Aklog, as manager of HCFP/Capital Partners III LLC		9/11/2017
^** Signature of Reporting Person		Date
/s/ Dr. Lishan Aklog, as manager of Pavilion Venture Partners LLC		9/11/2017
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.